Form 4: Elevation Oncology Director Acquires Stock Options

Timothy P. Clackson, a director of Elevation Oncology, Inc., acquired stock options for 35,000 shares on June 13, 2024.

Summary

• Timothy P. Clackson, a director at Elevation Oncology, Inc., filed a Form 4 with the SEC.
• The filing reports a transaction that occurred on June 13, 2024, where Clackson acquired stock options for 35,000 shares of Elevation Oncology's common stock.
• The exercise price of the stock options is $3.35.
• The options vest 100% on the one-year anniversary of the grant date, contingent on Clackson's continued service to the company.
• The expiration date for the options is June 12, 2034.
• Following the transaction, Clackson directly owns 35,000 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine filing indicating a director's stock option grant, which can be seen as a positive sign of alignment with company goals, but doesn't provide strong positive or negative signals.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

This is a standard SEC filing related to insider transactions. It's common for directors and officers of publicly traded companies to receive stock options as part of their compensation packages.

Stakeholder Impact

• The acquisition of stock options by a director could have a slightly positive impact on shareholders, as it aligns the director's interests with the company's success.

Key Dates